Spectrum of acute renal failure in the intensive care unit: The PICARD experience.
Acute renal failure (ARF) in the critically ill has been the topic of numerous reports over the past four decades. Many of these reports have focused on the associated high mortality rates; observational data from a broad range of centers have suggested in-hospital mortality rates in excess of 50% in most reported series [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Identification of risk factors, comparison of severity scores, and comparisons of nonrandomized treatment strategies (e.g., diuretic agents, dopamine, dialysis modality) have dominated this literature [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Arguably most striking has been the lack of obvious improvement in acute renal failure-associated mortality rates over time. Such a dilemma would typically stimulate clinical investigation, given vast potential for improvement. However, owing in part to wide variation in patient characteristics, practice patterns, and outcomes across centers and among published reports, even identifying major areas for potential intervention has been difficult. While several randomized clinical trials have been conducted in the more recent past [22] [23] [24] [25] , most have shown no benefit.
In an effort to develop a large registry of critically ill patients with ARF across multiple clinical sites, we created the Program to Improve Care in Acute Renal Disease (PICARD). The major goal of PICARD was to leverage the diversity of several sites and a relatively large sample of patients to better understand those demographic, process, renal, and nonrenal clinical factors associated with favorable and unfavorable outcomes, including mortality, nonrecovery of renal function, and resource utilization. In doing so, our hope was to provide a contemporary view of the disease process, and to identify those areas most suitable for intervention. In this manuscript, we describe the methods of patient selection and data acquisition, and the spectrum of collected clinical and process variables. We also report on major study outcomes, focusing on differences by clinical site, dialysis requirement, and etiology of acute renal failure. We hypothesized that there would be significant differences in patient characteristics, processes of care, and outcomes across clinical sites.
METHODS

Study participants
The evaluated by PICARD study personnel for potential study participation. Given the large number of ICU beds at CCF, one in six ARF patients were randomized for possible study inclusion, to avoid single center overrepresentation. Acute renal failure was defined as an increase in serum creatinine ≥0.5 mg/dL with baseline serum creatinine <1.5 mg/dL (new onset ARF), or an increase in serum creatinine ≥1.0 mg/dL with baseline serum creatinine ≥1.5 mg/dL and <5.0 mg/dL [ARF on chronic kidney disease (CKD)]. Patients with a baseline serum creatinine ≥5.0 mg/dL were not considered for study inclusion. Other exclusion criteria included age <18 years, previous dialysis, kidney transplantation, ARF from urinary tract obstruction and hypovolemia responsive to fluids; prisoners and pregnant patients were also excluded. Patients who were contacted by study personnel and who signed (or whose proxy signed) informed consents were enrolled in the study cohort. The reason for nonenrollment was determined for patients who did not sign informed consent [26] , although no additional data were collected for privacy considerations. The Committees on Human Research at each participating clinical site approved the study protocol and informed consent.
Data collection strategy
If the PICARD inclusion and exclusion criteria were met and informed consent obtained, the ICU chart was reviewed to determine on which hospital day the patient met ARF criteria. Data from the first ICU day, the first day on which ARF criteria were met, the day of consultation, and the three days preceding consultation were obtained (in some instances, these days overlapped, but were appropriately coded in the database to facilitate subsequent analyses). Following consultation, data were collected prospectively until three days after the end of consultation or ICU discharge, whichever came first. For patients with extended ICU stays or prolonged dialysis requirements, data were collected for up to 10 weeks after the day of consultation, or eight weeks after the start of dialysis. Finally, data on vital status, recovery of renal function, and ICU and hospital lengths of stay were collected on the day of hospital discharge.
Data management strategy
A scannable form was developed for data capture and entry using the Teleform Designer Module (Cardiff Software, San Diego, CA, USA). The Teleform Designer generated a unique internal form ID to identify individual forms. Each PICARD site was equipped with hardware and software to print forms locally with unique patient identifiers. Study coordinators completed the forms, which were then scanned and recognized by the Teleform Reader Module. Following editing and validation of data by the Teleform Verifier Module, the data were transferred directly into the Teleform database at each site. Site computers were connected to the UCSD Data Coordinating Center server via a virtual private network on the Internet. Data from the Teleform database were encrypted and transferred via the Internet to the SQL server using a Microsoft Peer to Peer Transfer protocol (MS PPTP; Microsoft, Redmond, WA, USA) for secure connections. The data were deidentified and subjected to a variety of rules and checks to identify any errors before ultimately being transferred to the PICARD database created in Microsoft SQL 7.0 using the Microsoft Data Engine (Microsoft). Data were backed up each night, and periodic audits were performed to establish the accuracy of data capture and transfer into the database.
Data elements
Multiple data elements (>800 per patient) were collected on each PICARD participant. Data elements included: demographics, comorbid conditions, hospital and ICU admission and discharge data, ICD-9 admission and discharge diagnosis codes, presumed etiologies of ARF, vital signs, urine output, volume status (including intake and output), surgical procedures, nonsurgical procedures (e.g., radiology, echocardiography, endoscopy), blood and urine laboratory studies including microbiology, medication use, and the use of parenteral and enteral nutrition. Multiple generic and ARF-specific severity scores were calculated based on the data obtained above. Organ failure was defined using validated published criteria [18] . Dialysis procedures were evaluated in exquisite detail, including data on vascular access, anticoagulation, blood and dialysate flow rates, hemofiltration solution and dialysate composition, ultrafiltration prescription and weight loss achieved, along with dialysisassociated medications, transfusions, and complications.
Outcomes
In-hospital mortality was the primary outcome; we also collected ICU mortality and 28-day mortality. Recovery of renal function was defined as dialysis independence for at least three days prior to discharge. We considered the combined outcome of death or nonrecovery (dialysis dependence) after ARF. Finally, we collected information on hospital and ICU lengths of stay.
Dialysis and nondialysis care
Intermittent dialysis was performed using volumetrically controlled, bicarbonate-based machines and synthetic biocompatible hemodialyzers. The indications, frequency, and duration of intermittent dialysis treatment were individualized for each patient based on prevalent practices at each clinical site. Continuous techniques included continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF determined by the treating nephrologists at each clinical site. There were no prespecified criteria for initiation or withdrawal of dialysis or for any aspect of dialysis care. Concurrent ICU care for each patient was determined by the treating physicians in conjuction with nephrologists. No interventions were instituted as part of the PICARD study.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation or median and interquartile range and compared using analysis of variance (general linear models with adjustment for multiple comparisons) or the Kruskal-Wallis test where appropriate. Categorical variables are expressed as proportions and compared with the Cochran-Mantel-Haenszel v 2 test or Fisher exact test. Two-tailed P values < 0.05 were considered significant. Statistical analyses were conducted using SAS 8.2 (SAS Insitute, Cary, NC, USA).
RESULTS
Baseline characteristics
There were 618 patients enrolled in PICARD. Demographic data were obtained on virtually all patients, as were data on comorbid conditions and the presumed etiology of ARF. Vital signs, urine output, and routine laboratory studies were obtained on more than 95% of patients. Data sufficient to calculate the Acute Physiology and Chronic Health Evaluation (APACHE) III and other severity of illness scores were available in 94% of patients. Other laboratory studies, procedures, and other data elements were similarly well captured, although less widely available due to the nonroutine nature of the information. As hypothesized, there were significant differences in numerous baseline characteristics, processes of care, and outcomes by site. Table 1 shows an array of baseline data from the day of consultation, stratified by clinical site. The mean age was 59.5 years, though varied widely across sites. The majority of patients were white, with a modest fraction of African American patients at four of five sites. There was a modest fraction of Hispanic and Asian/Pacific Islander patients, although these were derived exclusively from the two California sites. Comorbid conditions were common, although specific comorbidities varied widely by site. Patients at CCF and MMC had more extensive cardiovascular comorbidities (hypertension, coronary artery disease, and heart failure) owing in part to the older ARF populations served. In contrast, liver disease and immunosuppression were more common among patients at UCSD and UCSF. Respiratory failure was common among ARF patients at all sites. The distribution of other failed organ systems differed significantly. There were surprisingly few intersite differences in vital signs or body weight. The median urine outputs were lowest and the fraction of patients with oliguria highest at VU and UCSD. Mean leukocyte counts were elevated, and hemoglobin concentrations were reduced, consistent with a high incidence of infection and inflammation. The pH and bicarbonate concentrations were low, consistent with metabolic acidosis. Aside from the total bilirubin concentration (corresponding to the fraction of patients with acute and chronic liver disease), there were relatively few differences across sites in baseline laboratory data. Likewise, the distribution of presumed etiologies of ARF was relatively uniform, except for a lower fraction of patients with "prerenal" azotemia at MMC, and a higher fraction of patients with ARF associated with liver disease at UCSF. 
Dialysis status
Three hundred and ninety-eight (64%) patients were dialyzed for ARF. The overall utilization of continuous renal replacement therapy (CRRT) was high, with 60% of dialyzed patients receiving CRRT for all or part of their dialysis course. Figure 1 shows the distribution of patients by dialysis modality [none, intermittent hemodialysis (IHD) only, CRRT only, IHD followed by CRRT, and CRRT followed by IHD] and stratified by site. Patients at MMC (63%) and VU (70%) were more likely to undergo IHD alone than patients at the other three sites (24% to 34%). Table 2 shows the frequency of baseline characteristics by dialysis status. Patients who did not require dialysis were more likely to have been hypertensive with a history of coronary artery disease. Higher urine output and lower APACHE III scores were also associated with nondialysis-requiring ARF. The heart rates were higher, and systolic, diastolic, and mean arterial blood pressures lower among patients treated with CRRT. Continuous therapy use was also associated with acute hepatic failure and the total bilirubin concentration.
Mortality, mortality or nonrecovery, and lengths of stay
The overall in-hospital mortality rate was 37% (231/618). The 28-day mortality rate was 22% (138/617; the admission date was missing for one patient), and the ICU mortality rate was 32% (199/618). Figure 2 shows overall and site-specific in-hospital mortality by dialysis status-no dialysis, IHD only, CRRT only, and combined IHD + CRRT by initial dialysis modality. As expected, inhospital mortality rates were higher among patients who required dialysis, particularly those selected for CRRT. Patients with ARF superimposed on CKD had lower mortality rates than those with new-onset ARF (31% vs. 41%, P = 0.03). Figure 3 shows overall and site-specific in-hospital mortality rates by the presumed etiology of ARF. For these analyses, mutually exclusive categories were created-ischemic ATN, nephrotoxic ARF, both, and other. There was no relation between presumed etiology of ARF and in-hospital mortality. An expanded description of the presumed etiology of ARF (allowing more than one etiology per case) is shown in Table 4 . Figures 4 and 5 show the combined outcome of mortality or nonrecovery by dialysis status and ARF etiology, respectively. When considering the combined outcome of mortality or nonrecovery compared with mortality alone, the differences among dialysis modalities were attenuated. Mortality rates were related to the severity of extrarenal disease. Figure 6 shows overall and site-specific in-hospital mortality rates by the number of failed organ systems (an additive sum of cardiovascular, hepatic, hematologic, neurologic, renal, and respiratory failure). Mortality rates exceeded 50% with four or more failed organ systems. The median hospital length of stay was 25 days (26 days when excluding patients who died).
DISCUSSION
The PICARD cohort may be the most comprehensive registry of critically ill patients with ARF assembled to date. Nonetheless, the study could not have been conceived or implemented without the prior work conducted by many committed investigators over the past [3] , Liano et al [4, 6] , and others [15, [28] [29] [30] [31] have also suggested that while overall mortality rates associated with ARF have not materially improved, the number and complexity of extrarenal complications in patients with ARF has indeed increased. Table 3 summarizes ARF-associated mortality rates derived from several more recently published studies. Data from PICARD suggest that the trend toward more complicated ARF continues into the 21st century. More than half of patients with ARF in the ICU require dialysis, and a large fraction has significant hemodynamic instability. Among the 134 patients who required dialysis and were assigned to CRRT alone, the average mean arterial blood pressure was below 70 mm Hg despite the use of pressor agents. These same patients had, on average, between three and four failed organ systems. Therefore, despite crude mortality rates that have remained high, it is reasonable to conclude that outcomes associated with ARF in the critically ill have indeed improved, at least marginally, in the recent past.
There are several limitations to the information presented here. First, PICARD included academic medical centers providing extensive tertiary care. Therefore, we may have overestimated the associated comorbidity and severity of illness relative to what would be expected across institutions providing mainly primary and community-based care. Second, it is difficult to categorize the presumed etiology of ARF by clinical criteria. Given considerable overlap and potential misclassification, we may have erred in not identifying etiology-specific differences in mortality or nonrecovery. More precise determinations of the etiology of ARF, including biopsy, would be desirable in future studies. Third, because patients were identified after nephrology consultation, we did not ascertain cases that might have "qualified" by ARF diagnosis criteria but were not deemed sick enough to require consultation, or who were so sick that nephrology consultation was considered irrelevant. The requirement that participants or their proxies signed informed consent was associated with a large fraction of potential cases not being enrolled [26] . While detailed data were not available on nonenrolled patients, many were not enrolled because they expired before informed consent could be obtained. In other words, patients who were healthy enough to sign informed consent (or who had attendant family members or friends) were likely to be different than "all comers" with ARF in the ICU. Therefore, PICARD may have underestimated ARF-associated mortality rates at the participating institutions. Finally, we demonstrated wide variation across sites, and the number of sites was relatively small. Incorporating additional sites in future efforts should provide an even clearer picture of contemporary ARF in the ICU.
CONCLUSION
ARF in the critically ill remains an extremely important problem facing nephrologists and other intensivists. The proportion of patients requiring dialysis is high; institutions with continuous dialysis capability appear to be using these techniques with increasing frequency. There is a considerable burden of extrarenal disease affecting patients before or concurrent with the ARF episode. There is wide variation across institutions in patient characteristics and practice patterns. These differences highlight the need for additional multicenter observational and interventional studies in ARF.
